Porzsolt F - Search Results

1

Quality of life in oncology practice: prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy.

Coates A, Porzsolt F, Osoba D. Coates A, et al. Among authors: porzsolt f. Eur J Cancer. 1997 Jun;33(7):1025-30. doi: 10.1016/s0959-8049(97)00049-x. Eur J Cancer. 1997. PMID: 9376182

2

Practical aspects of quality-of-life measurement: design and feasibility study of the quality-of-life recorder and the standardized measurement of quality of life in an outpatient clinic.

Sigle J, Porzsolt F. Sigle J, et al. Among authors: porzsolt f. Cancer Treat Rev. 1996 Jan;22 Suppl A:75-89. doi: 10.1016/s0305-7372(96)90067-5. Cancer Treat Rev. 1996. PMID: 8625353 No abstract available.

3

Treatment decisions in palliative cancer care: patients' preferences for involvement and doctors' knowledge about it.

Rothenbacher D, Lutz MP, Porzsolt F. Rothenbacher D, et al. Among authors: porzsolt f. Eur J Cancer. 1997 Jul;33(8):1184-9. doi: 10.1016/s0959-8049(97)00034-8. Eur J Cancer. 1997. PMID: 9301440

4

Quality assurance by specification and achievement of goals in palliative cancer treatment.

Porzsolt F, Wirth A, Mayer-Steinacker R, Schulte M, Negri G, Suhr P, Link KH, Gaus W, Röttinger EM. Porzsolt F, et al. Cancer Treat Rev. 1996 Jan;22 Suppl A:41-9. doi: 10.1016/s0305-7372(96)90062-6. Cancer Treat Rev. 1996. PMID: 8625348

5

Goals of palliative cancer therapy: scope of the problem.

Porzsolt F. Porzsolt F. Cancer Treat Rev. 1993;19 Suppl A:3-14. doi: 10.1016/0305-7372(93)90052-s. Cancer Treat Rev. 1993. PMID: 7679318 Review.

6

Pharmacokinetics and biological activity in subcutaneous long-term administration of recombinant interferon-gamma in cancer patients.

Digel W, Zahn G, Heinzel G, Porzsolt F. Digel W, et al. Among authors: porzsolt f. Cancer Immunol Immunother. 1991;34(3):169-74. doi: 10.1007/BF01742308. Cancer Immunol Immunother. 1991. PMID: 1756534 Clinical Trial.

7

Treatment of advanced renal cell cancer with recombinant interferon alpha as a single agent and in combination with medroxyprogesterone acetate. A randomized multicenter trial.

Porzsolt F, Messerer D, Hautmann R, Gottwald A, Sparwasser H, Stockamp K, Aulitzky W, Moormann JG, Schumacher K, Rasche H, et al. Porzsolt F, et al. J Cancer Res Clin Oncol. 1988;114(1):95-100. doi: 10.1007/BF00390492. J Cancer Res Clin Oncol. 1988. PMID: 2965154 Clinical Trial.

8

[Advantages and problems of interdisciplinary tumor conferences].

Heimpel H, Loetzke E, Porzsolt F. Heimpel H, et al. Among authors: porzsolt f. Langenbecks Arch Chir Suppl II Verh Dtsch Ges Chir. 1990:55-8. Langenbecks Arch Chir Suppl II Verh Dtsch Ges Chir. 1990. PMID: 1983608 German.

9

Predictors of successful cancer prevention programs.

Porzsolt F, Kirner A, Kaplan RM. Porzsolt F, et al. Recent Results Cancer Res. 2009;181:19-31. doi: 10.1007/978-3-540-69297-3_2. Recent Results Cancer Res. 2009. PMID: 19213553 Review.

10

Preferences of diabetes patients and physicians: a feasibility study to identify the key indicators for appraisal of health care values.

Porzsolt F, Clouth J, Deutschmann M, Hippler HJ. Porzsolt F, et al. Health Qual Life Outcomes. 2010 Nov 4;8:125. doi: 10.1186/1477-7525-8-125. Health Qual Life Outcomes. 2010. PMID: 21050469 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results